Genfit (GNFTF) to Release Quarterly Earnings on Thursday

Genfit (OTCMKTS:GNFTF) is anticipated to announce its resultson Thursday, April 2nd. Analysts expect Genfit to post earnings of ($0.0352) per share and revenue of $42.1650 million for the quarter.

Genfit Trading Down 4.1%

Genfit stock opened at $10.43 on Thursday. The firm has a 50 day simple moving average of $8.47 and a 200 day simple moving average of $5.71. Genfit has a 1-year low of $4.14 and a 1-year high of $10.88.

Genfit Company Profile

Genfit is a clinical‐stage biopharmaceutical company headquartered in Lille, France, specializing in the development of innovative therapies and diagnostics for liver and metabolic diseases. The company’s research and development efforts are primarily focused on non‐alcoholic steatohepatitis (NASH), a progressive liver disorder with significant unmet medical needs. Genfit’s lead therapeutic candidate, elafibranor, is designed to target key pathways involved in inflammation, fibrosis and lipid metabolism, positioning it as a potential treatment for patients with NASH and associated metabolic complications.

In addition to its therapeutic pipeline, Genfit has established a diagnostic arm centered on NIS4®, a proprietary blood‐based test that leverages transcriptomic biomarkers to enable earlier and more accurate detection of liver fibrosis in patients at risk for NASH.